AstraZeneca unveils new data from ‘diverse pipeline’ at ASH

The company stated: “AstraZeneca (AZN) advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology, ASH, Annual Meeting and Exposition, December 6-9, 2025. This year’s ASH congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include: Phase I trial of surovatamig: Updated results at three-year follow up from the ongoing first-in-human trial of surovatamig, a CD19xCD3 T-cell engager, in relapsed/refractory follicular lymphoma (Oral Abstract #1005). DURGA-1 Phase Ib/II study: Initial data for AZD0120 in patients with R/R multiple myeloma (MM). AZD0120 is an investigational BCMAxCD19 chimeric antigen receptor T-cell therapy (Oral Abstract #269). ECHO Phase III trial: Results after 50 months of follow up evaluating CALQUENCE(R) (acalabrutinib) plus bendamustine and rituximab in the first-line treatment of mantle cell lymphoma (Oral Abstract #885). ALXN1210-TMA-314 Phase III trial: Additional results from the open-label trial evaluating ULTOMIRIS(R) (ravulizumab-cwvz) in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) (Oral Abstract #1052).”